Compare · CFMS vs STE
CFMS vs STE
Side-by-side comparison of Conformis Inc. (CFMS) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CFMS and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.52B, about 195.6x CFMS ($104.9M).
- STE has hit the wire 16 times in the past 4 weeks while CFMS has been quiet.
- STE has more recent analyst coverage (16 ratings vs 2 for CFMS).
- Company
- Conformis Inc.
- STERIS plc (Ireland)
- Price
- $2.27+0.22%
- $210.28+0.27%
- Market cap
- $104.9M
- $20.52B
- 1M return
- -
- -0.96%
- 1Y return
- -
- -13.61%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 0
- 16
- Recent ratings
- 2
- 16
Conformis Inc.
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest CFMS
- SEC Form 15-12G filed by Conformis Inc.
- restor3d Completes Acquisition of Conformis
- SEC Form 4: Fischetti Gary P returned 10,470 shares to the company, closing all direct ownership in the company
- SEC Form 4: Johnston Philip W returned 19,273 shares to the company, closing all direct ownership in the company
- SEC Form 4: Augusti Mark A was granted 17,778 shares and returned 190,277 shares to the company, closing all direct ownership in the company
- SEC Form 4: Bienkowski Carrie returned 19,909 shares to the company, closing all direct ownership in the company
- SEC Form 4: Pedulla Denise E returned 18,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Langdale Bradley returned 18,379 shares to the company, closing all direct ownership in the company
- SEC Form 4: Fallon Kenneth P Iii returned 20,320 shares to the company, closing all direct ownership in the company
- SEC Form 4: Desrochers Christine returned 81,465 shares to the company, closing all direct ownership in the company
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 337 units of Ordinary Shares, decreasing direct ownership by 1% to 33,332 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 81 units of Ordinary Shares, decreasing direct ownership by 1% to 5,614 units (SEC Form 4)
- VP, Chf. Comp. & Quality Offc. Mcgowan Lindsey covered exercise/tax liability with 198 units of Ordinary Shares, decreasing direct ownership by 4% to 4,830 units (SEC Form 4)
- SVP and President, Healthcare Majors Cary L covered exercise/tax liability with 768 units of Ordinary Shares, decreasing direct ownership by 6% to 12,659 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 208 units of Ordinary Shares, decreasing direct ownership by 2% to 10,502 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 109 units of Ordinary Shares, decreasing direct ownership by 1% to 9,533 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 673 units of Ordinary Shares, decreasing direct ownership by 5% to 12,209 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 99 units of Ordinary Shares, decreasing direct ownership by 1% to 8,205 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,254 units of Ordinary Shares, decreasing direct ownership by 2% to 49,842 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)